Company / Free Cash Flow
Haemonetics Free Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$142.4M
FY2024
5-year range
$75.8M / $143.6M
FY2020-FY2024
Trend
-0.8%
vs FY2023
Sector context
#72 of 145
Health Care
What the data says
At $142M, Haemonetics's free cash flow ranks #72 of 145 in the Health Care sector. Free Cash Flow has fluctuated over the past 9 years, ranging from $40M in FY2018 to $146M in FY2017.
Based on SEC 10-K filings.
$142M in FY2024 with a 5-year CAGR of +5.4%.
Improved from $82M to $142M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +23.4%
- 5-Year CAGR
- +5.4%
- 10-Year CAGR
- -
Sector benchmark
#72 of 145 in Health CareTop 50% of 145This company $142.4M Sector average $770.9M
▼
-81.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.4%, indicating consistent growth.
- In FY2024, free cash flow decreased 0.8% year-over-year.
- Ranks #72 out of 145 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $142.4M | -0.8% |
| FY2023 | $143.6M | +75.7% |
| FY2022 | $81.7M | +7.9% |
| FY2021 | $75.8M | +5.6% |
| FY2020 | $71.8M | -34.4% |
| FY2019 | $109.5M | +171.5% |
| FY2018 | $40.3M | -72.3% |
| FY2017 | $145.6M | +74.1% |
| FY2016 | $83.6M | +329.6% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026